• 1
    Bozette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003; 348: 702710.
  • 2
    Friis-Moller N, Weber R, Reiss P et al. Cardiovascular disease risk factors in HIV patients–association with antiretroviral therapy. Results from the DAD study. AIDS 2003; 17: 11791193.
  • 3
    Mary-Krause M, Cotte L, Simon A, Partisani M, Costagliola D and the Clinical Epidemiology Group from the French Hospital Database. Increased risk of myocardial infarction with duration of protease inhibitor therapy in HIV-infected men. AIDS 2003; 17: 24792486.
  • 4
    The Data Collection on Adverse Events of Anti-HIV Drugs: (DAD) Study Group. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 19932003.
  • 5
    Holmberg SD, Moorman AC, Williamson JM et al. Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 2002; 360: 17471748.
  • 6
    Seminari E, Pan A, Voltini G et al. Assessment of atherosclerosis using carotid ultrasonography in a cohort of HIV-positive patients treated with protease inhibitors. Atherosclerosis 2002; 162: 433438.
  • 7
    Chironi G, Escaut L, Gariepy J et al. Carotid intima-media thickness in heavily pretreated HIV-infected patients. J Acquir Immune Defic Syndr 2003; 32: 490493.
  • 8
    Mercie P, Thiebaut R, Lavignolle V et al. Evaluation of cardiovascular risk factors in HIV-1 infected patients using carotid intima-media thickness measurement. Ann Med 2002; 34: 5563.
  • 9
    Hsue PY, Lo JC, Franklin A et al. Progression of atherosclerosis as assessed by carotid intima-media thickness in patients with HIV infection. Circulation 2004; 109: 16031608.
  • 10
    Maggi P, Serio G, Epifani G et al. Premature lesions of the carotid vessels in HIV-1-infected patients treated with protease-inhibitors. AIDS 2000; 14: F123F128.
  • 11
    Depairon M, Chessex S, Sudre P et al. Premature atherosclerosis in HIV-infected individuals–focus on protease inhibitor therapy. AIDS 2001; 15: 329334.
  • 12
    Graf S, Gariepy J, Massoneau M et al. Experimental and clinical validation of arterial diameter waveform and intima media thickness obtained from B-mode ultrasound image processing. Ultrasound Med Biol 1999; 25: 13531363.
  • 13
    Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: a direct measurement with ultrasound imaging. Circulation 1986; 74: 13991406.
  • 14
    Grobbee DE, Bots ML. Carotid artery intima-media thickness as an indicator of generalized atherosclerosis. J Intern Med 1994; 236: 567573.
  • 15
    Kanters SD, Algra A, van Leeuwen MS, Banga JD. Reproducibility of in vivo carotid intima-media thickness measurements. A review. Stroke 1997; 28: 665671.
  • 16
    Simon A, Megnien JL, Levenson J. Coronary risk estimation and treatment of hypercholesterolemia. Circulation 1997; 96: 24492452.
  • 17
    Howard G, Sharrett A, Heiss G. Carotid artery intima-medial thickness. Distribution in general populations as evaluated by B-mode ultrasound. Stroke 1993; 24: 12971304.
  • 18
    Salonen JT, Salonen R. Ultrasound B mode imaging in observational studies of atherosclerosis. Circulation 1993; 8 (Suppl. II): II-5II-65.
  • 19
    Maggi P, Lillo A, Perilli F, Maserati R, Chirianni A on behalf of the PREVALEAT Group. Color-doppler ultrasonography of carotid vessels in patients treated with antiretroviral therapy: a comparative study. AIDS 2004; 18: 10231028.
  • 20
    Phipps RP, Koumas L, Leung E, Reddy SY, Blieden T, Kaufman J. The CD40-CD40 ligand system: a potential therapeutic target in atherosclerosis. Curr Opin Invest Drugs 2001; 2: 773777.
  • 21
    Mutimer HP, Akatsuka Y, Manley T et al. Association between immune recovery uveitis and a diverse introcular cytomegalovirus-specific cytotoxic T cell response. J Infect Dis 2002; 186: 701705.
  • 22
    Birdsall HH, Trial J, Lin HJ et al. Transendothelial migration of lymphocytes from HIV-1-infected donors: a mechanism for extravascular dissemination of HIV-1. J Immunol 1997; 158: 59685977.
  • 23
    Hollenbaugh D, Grosmaire LS, Kullas CD et al. The human T cell antigen gp39, a member of the TNF gene family, is a ligand for the CD40 receptor: expression of a soluble form of gp39 with B cell co-stimulatory activity. EMBO J 1992; 11: 43134321.
  • 24
    Henn V, Slupsky JR, Grafe M et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591594.
  • 25
    Aukrust P, Muller F, Ueland T et al. Enhanced levels of soluble and membrane-bound CD40 ligand in patients with unstable angina. Possible reflection of T lymphocyte and platelet involvement in the pathogenesis of acute coronary syndromes. Circulation 1999; 100: 614620.
  • 26
    Mercié P, Thiébaut R, Aurillac-Lavignolle V, Pellegrin JL, Yvorra-Vives MC, Cipriano C, Neau D, Morlat P, Ragnaud JM, Dupon M, Malvy D, Lawson-Ayayi S, Roudaut R, Dabis F, on behalf of the GECSA. Carotid intima-media thickness increases over time in HIV-1 Infected Patients. 5th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV. Antiviral Therapy 2003; 8: L6 [abstract 2].